Related Experiment Video
Updated: Mar 20, 2026
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
Published on: January 20, 2023
Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple
Despoina Papathemeli1, Ronald Gräfe2, Uwe Hildebrandt3
1Department of Dermatology and Venereology, Harzklinikum Dorothea Christiane Erxleben, Quedlinburg, Germany dpapathem@live.com.
Background:
The appearance of solid tumors und lymphomas during treatment with fingolimod was observed in studies and has been described in case reports.
Objective:
To report a case of primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis (MS) with fingolimod.
Methods:
Case study.
Results:
Our patient developed a lymphoma a few weeks after initialization of therapy with fingolimod; 5 weeks after discontinuation of treatment the lesions resolved.
Conclusion:
Causality of fingolimod is indicated by the fact that the skin lesions appeared after commencement of treatment and resolved after discontinuation of therapy. This case serves as a reminder of the potential side effects of fingolimod.
